<VariationArchive VariationID="12048" VariationName="NM_000136.3(FANCC):c.1555dup (p.Thr519fs)" VariationType="Duplication" Accession="VCV000012048" Version="6" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-02-28" DateCreated="2015-06-18" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="27087" VariationID="12048">
      <GeneList>
        <Gene Symbol="AOPEP" FullName="aminopeptidase O (putative)" GeneID="84909" HGNC_ID="HGNC:1361" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>9q22.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="94726699" stop="95150224" display_start="94726699" display_stop="95150224" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="97488950" stop="97849499" display_start="97488950" display_stop="97849499" Strand="+" />
          </Location>
          <OMIM>619600</OMIM>
        </Gene>
        <Gene Symbol="FANCC" FullName="FA complementation group C" GeneID="2176" HGNC_ID="HGNC:3584" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>9q22.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="95099054" stop="95317709" display_start="95099054" display_stop="95317709" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="97861335" stop="98079990" display_start="97861335" display_stop="98079990" Strand="-" />
          </Location>
          <OMIM>613899</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000136.3(FANCC):c.1555dup (p.Thr519fs)</Name>
      <CanonicalSPDI>NC_000009.12:95101828:TT:TTT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>9q22.32</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="95101828" stop="95101829" display_start="95101828" display_stop="95101829" variantLength="1" positionVCF="95101828" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="97864110" stop="97864111" display_start="97864110" display_stop="97864111" variantLength="1" positionVCF="97864110" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
      </Location>
      <ProteinChange>T519fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000136.2" sequenceAccession="NM_000136" sequenceVersion="2" change="c.1555dupA">
            <Expression>NM_000136.2:c.1555dupA</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.11" sequenceAccession="NC_000009" sequenceVersion="11" change="g.97864112dup" Assembly="GRCh37">
            <Expression>NC_000009.11:g.97864112dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000136.3" sequenceAccession="NM_000136" sequenceVersion="3" change="c.1555dup" MANESelect="true">
            <Expression>NM_000136.3:c.1555dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000127.2" sequenceAccession="NP_000127" sequenceVersion="2" change="p.Thr519fs">
            <Expression>NP_000127.2:p.Thr519fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001243743.2" sequenceAccession="NM_001243743" sequenceVersion="2" change="c.1555dup">
            <Expression>NM_001243743.2:c.1555dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001230672.1" sequenceAccession="NP_001230672" sequenceVersion="1" change="p.Thr519fs">
            <Expression>NP_001230672.1:p.Thr519fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.12" sequenceAccession="NC_000009" sequenceVersion="12" change="g.95101830dup" Assembly="GRCh38">
            <Expression>NC_000009.12:g.95101830dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011707.1" sequenceAccession="NG_011707" sequenceVersion="1" change="g.220881dup">
            <Expression>NG_011707.1:g.220881dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_497" sequenceAccession="LRG_497">
            <Expression>LRG_497:g.220881dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_497t1" sequenceAccession="LRG_497t1">
            <Expression>LRG_497t1:c.1555dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA256206" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="613899.0006" DB="OMIM" />
        <XRef Type="rs" ID="794726667" DB="dbSNP" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff reviewed the sequence information reported in PubMed 1574115, cited by PubMed 8829660, to determine the location of this allele on the current reference sequence.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000136.3(FANCC):c.1555dup (p.Thr519fs) AND Fanconi anemia complementation group C" Accession="RCV000012828" Version="5">
        <ClassifiedConditionList TraitSetID="3252">
          <ClassifiedCondition DB="MedGen" ID="C3468041">Fanconi anemia complementation group C</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-07-29" SubmissionCount="2">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000136.3(FANCC):c.1555dup (p.Thr519fs) AND Fanconi anemia" Accession="RCV001851810" Version="3">
        <ClassifiedConditionList TraitSetID="6447">
          <ClassifiedCondition DB="MedGen" ID="C0015625">Fanconi anemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-02-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-02-01" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2015-06-18" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16445838</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24584348</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8103176</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8829660</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8882868</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9272737</ID>
        </Citation>
        <DescriptionHistory Dated="2022-03-25">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2021-08-07">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="6447" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1797" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Fanconi pancytopenia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fanconi's anemia</ElementValue>
                <XRef ID="Fanconi+Anemia/2780" DB="Genetic Alliance" />
                <XRef ID="30575002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia</ElementValue>
                <XRef ID="MONDO:0019391" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS227650" DB="OMIM" />
                <XRef ID="84" DB="Orphanet" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FA</ElementValue>
                <XRef Type="MIM" ID="227650" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6425" />
                <XRef ID="6425" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management, 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/images/uploads/other/Fanconi_Anemia_Clinical_Care_Guidelines_5thEdition_web.pdf</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C0015625" DB="MedGen" />
              <XRef ID="D005199" DB="MeSH" />
              <XRef ID="MONDO:0019391" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS227650" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="3252" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10927" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">FANCONI PANCYTOPENIA, TYPE 3</ElementValue>
                <XRef Type="MIM" ID="227645" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">FACC</ElementValue>
                <XRef Type="MIM" ID="227645" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fanconi anemia, group C</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group C</ElementValue>
                <XRef ID="MONDO:0009213" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FA3</ElementValue>
                <XRef Type="MIM" ID="227645" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FAC</ElementValue>
                <XRef Type="MIM" ID="227645" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">FANCC</ElementValue>
                <XRef Type="MIM" ID="227645" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">FANCC-Related Fanconi Anemia</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15168" />
                <XRef ID="15168" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management, 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2011">
                <URL>http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Carrier-Screening-ACT-SheetAshkenazi-Jewish-Genetic-Disorders.aspx</URL>
                <CitationText>American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/images/uploads/other/Fanconi_Anemia_Clinical_Care_Guidelines_5thEdition_web.pdf</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C3468041" DB="MedGen" />
              <XRef ID="MONDO:0009213" DB="MONDO" />
              <XRef Type="MIM" ID="227645" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="33068" SubmissionDate="2019-11-07" DateLastUpdated="2019-11-09" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="613899.0006_FANCONI ANEMIA, COMPLEMENTATION GROUP C" title="FANCC, 1-BP INS, 1806A_FANCONI ANEMIA, COMPLEMENTATION GROUP C" />
        <ClinVarAccession Accession="SCV000033068" DateUpdated="2019-11-09" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1996-01-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Lo Ten Foe et al. (1996) described a frameshift mutation in the FANCC gene resulting from insertion of an adenine after nucleotide 1806 in exon 14. The insertion caused a frameshift that was expected to give rise to a truncated protein of 526 amino acids, which is shorter than the protein resulting from premature termination caused by the R548X mutation (613899.0005), and therefore presumed to be inactive. Mutations in exon 14 are the most C-terminal of 7 pathogenic mutations that the authors discussed. Three pathogenic mutations are located in exon 14, suggesting that the C-terminal part of FAC protein is essential for an as yet unknown function. The other 2 exon 14 mutations reported to that time were L554P (613899.0001) and R548X (613899.0005).</Attribute>
              <Citation>
                <ID Source="PubMed">8829660</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FANCC" />
          </GeneList>
          <Name>FANCC, 1-BP INS, 1806A</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP INS, 1806A</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="613899.0006" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">FANCONI ANEMIA, COMPLEMENTATION GROUP C</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3484113" SubmissionDate="2021-08-05" DateLastUpdated="2021-08-07" DateCreated="2021-08-07">
        <ClinVarSubmissionID localKey="NM_000136.2:c.1555dupA|MedGen:C3468041" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001774552" DateUpdated="2021-08-07" DateCreated="2021-08-07" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-07-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8882868</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16445838</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9272737</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8829660</ID>
          </Citation>
          <Comment>Variant summary: FANCC c.1555dupA (p.Thr519AsnfsX9) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. p.Arg548X). The variant was absent in 251020 control chromosomes (gnomAD). c.1555dupA (also described in the literature as 1806insA) has been reported in compound heterozygosity with another pathogenic variant in one individual (Lo Ten Foe_1996). This individual was reported with normal complete blood cell count and observed phenotypic reversion to MMC resistance which was determined to be due to a detected mitotic crossover event between the mutated sites deduced to have occurred in the patient's hematopoietic system which lead to the production of a wild-type allele and an allele having the two mutations in cis (Lo Ten Foe_1997). Nevertheless, Lo Ten Foe et al (1996) using a functional assay demonstrated that the specific variant was not capable of restoring MMC hypersensitivity. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FANCC" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000136.2:c.1555dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3468041" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10156071</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4169158" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="839806|MedGen:C0015625" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002148940" DateUpdated="2024-02-20" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-02-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8103176</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8882868</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24584348</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8882868</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8829660</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the FANCC protein in which other variant(s) (p.Arg548*) have been determined to be pathogenic (PMID: 8103176, 8882868, 24584348). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. Experimental studies have shown that this premature translational stop signal affects FANCC function (PMID: 8882868). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. ClinVar contains an entry for this variant (Variation ID: 12048). This variant is also known as 1806insA. This premature translational stop signal has been observed in individual(s) with clinical features of Fanconi anemia (PMID: 8829660). This variant is present in population databases (rs794726667, gnomAD 0.007%). This sequence change creates a premature translational stop signal (p.Thr519Asnfs*9) in the FANCC gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 40 amino acid(s) of the FANCC protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FANCC" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000009.11:g.97864110_97864111insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0015625" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="33068" TraitType="Disease" MappingType="Name" MappingValue="FANCONI ANEMIA, COMPLEMENTATION GROUP C" MappingRef="Preferred">
        <MedGen CUI="C3468041" Name="Fanconi anemia complementation group C" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3484113" TraitType="Disease" MappingType="XRef" MappingValue="C3468041" MappingRef="MedGen">
        <MedGen CUI="C3468041" Name="Fanconi anemia complementation group C" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4169158" TraitType="Disease" MappingType="XRef" MappingValue="C0015625" MappingRef="MedGen">
        <MedGen CUI="C0015625" Name="Fanconi anemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

